JP2019089848A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019089848A5 JP2019089848A5 JP2019041615A JP2019041615A JP2019089848A5 JP 2019089848 A5 JP2019089848 A5 JP 2019089848A5 JP 2019041615 A JP2019041615 A JP 2019041615A JP 2019041615 A JP2019041615 A JP 2019041615A JP 2019089848 A5 JP2019089848 A5 JP 2019089848A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- medical device
- group
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 238000000034 method Methods 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 239000003960 organic solvent Substances 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000012296 anti-solvent Substances 0.000 claims 2
- -1 ligroin Chemical compound 0.000 claims 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 2
- 239000003495 polar organic solvent Substances 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078418A JP2021121601A (ja) | 2013-03-15 | 2021-05-06 | ラパマイシン誘導体の精製 |
| JP2023136964A JP2023164476A (ja) | 2013-03-15 | 2023-08-25 | ラパマイシン誘導体の精製 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799857P | 2013-03-15 | 2013-03-15 | |
| US61/799,857 | 2013-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503426A Division JP2016519086A (ja) | 2013-03-15 | 2014-03-17 | ラパマイシン誘導体の精製 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078418A Division JP2021121601A (ja) | 2013-03-15 | 2021-05-06 | ラパマイシン誘導体の精製 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019089848A JP2019089848A (ja) | 2019-06-13 |
| JP2019089848A5 true JP2019089848A5 (enExample) | 2019-08-29 |
Family
ID=51538094
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503426A Withdrawn JP2016519086A (ja) | 2013-03-15 | 2014-03-17 | ラパマイシン誘導体の精製 |
| JP2019041615A Pending JP2019089848A (ja) | 2013-03-15 | 2019-03-07 | ラパマイシン誘導体の精製 |
| JP2021078418A Pending JP2021121601A (ja) | 2013-03-15 | 2021-05-06 | ラパマイシン誘導体の精製 |
| JP2023136964A Pending JP2023164476A (ja) | 2013-03-15 | 2023-08-25 | ラパマイシン誘導体の精製 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503426A Withdrawn JP2016519086A (ja) | 2013-03-15 | 2014-03-17 | ラパマイシン誘導体の精製 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078418A Pending JP2021121601A (ja) | 2013-03-15 | 2021-05-06 | ラパマイシン誘導体の精製 |
| JP2023136964A Pending JP2023164476A (ja) | 2013-03-15 | 2023-08-25 | ラパマイシン誘導体の精製 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9598439B2 (enExample) |
| EP (1) | EP2972258B1 (enExample) |
| JP (4) | JP2016519086A (enExample) |
| CN (2) | CN105102967B (enExample) |
| CA (1) | CA2901162C (enExample) |
| ES (1) | ES2897473T3 (enExample) |
| SG (3) | SG10202112135VA (enExample) |
| WO (1) | WO2014145780A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2777841C (en) | 2009-11-02 | 2017-01-17 | Francis M. Creighton | Magnetomotive stator system and methods for wireless control of magnetic rotors |
| CA2901162C (en) | 2013-03-15 | 2021-06-01 | Biosensors International Group, Ltd. | Purification of rapamycin derivatives |
| CN109851626B (zh) * | 2019-01-08 | 2021-11-02 | 扬子江药业集团四川海蓉药业有限公司 | 一种替西罗莫司的分离纯化方法 |
| CN116102576B (zh) * | 2021-11-09 | 2025-08-29 | 上海博畅医疗科技有限公司 | 一种优美莫司晶体的制造方法及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9713730D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| US20060198867A1 (en) * | 1997-09-25 | 2006-09-07 | Abbott Laboratories, Inc. | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
| US7452692B2 (en) | 2002-02-13 | 2008-11-18 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Method for extracting a macrolide from biomatter |
| TW200504079A (en) * | 2003-03-31 | 2005-02-01 | Biogal Gyogyszergyar | Crystallization and purification of macrolides |
| US7220755B2 (en) * | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| EP1697383B1 (en) * | 2003-12-05 | 2014-04-23 | Biocon Limited | Process for the purification of tacrolimus |
| JP4716280B2 (ja) * | 2004-03-01 | 2011-07-06 | テルモ株式会社 | Ｏ−アルキル化ラパマイシン誘導体の製造法 |
| CN1942476A (zh) * | 2004-04-14 | 2007-04-04 | 惠氏公司 | 纳巴霉素42－酯衍生物的区位特异合成 |
| EP1817314A1 (en) | 2004-12-01 | 2007-08-15 | Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság | Non-hygroscopic and powdery amorphous pimecrolimus |
| KR20070107087A (ko) * | 2005-03-02 | 2007-11-06 | 와이어쓰 | 라파마이신의 정제 |
| US20060222627A1 (en) * | 2005-03-30 | 2006-10-05 | Andrew Carter | Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue |
| TW200736603A (en) * | 2005-12-07 | 2007-10-01 | Wyeth Corp | Methods for preparing crystalline rapamycin and measuring crystallinity of rapamycin compounds using differential scanning calorimetry |
| US7700614B2 (en) * | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
| GB0601406D0 (en) * | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| EP1993610A2 (en) | 2006-03-07 | 2008-11-26 | Wyeth | Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
| US7812032B2 (en) * | 2006-07-25 | 2010-10-12 | Abbott Laboratories | Crystalline forms of rapamycin analogs |
| US7820812B2 (en) * | 2006-07-25 | 2010-10-26 | Abbott Laboratories | Methods of manufacturing crystalline forms of rapamycin analogs |
| JP2010509317A (ja) * | 2006-11-10 | 2010-03-25 | バイオコン リミテッド | 純粋な形態のラパマイシンならびにこの回収方法および精製方法 |
| JP5456321B2 (ja) | 2006-11-27 | 2014-03-26 | テルモ株式会社 | Ｏ−アルキル化ラパマイシン誘導体の製造方法およびｏ−アルキル化ラパマイシン誘導体 |
| US20080287675A1 (en) * | 2007-05-18 | 2008-11-20 | Abbott Laboratories | Cascade system |
| CN101077334A (zh) * | 2007-06-29 | 2007-11-28 | 济南康泉医药科技有限公司 | 含酪氨酸激酶抑制剂的抗癌组合物 |
| TW200948361A (en) * | 2008-05-26 | 2009-12-01 | Chunghwa Chemical Synthesis & Biotech Co Ltd | Method for synthesizing Biolimus A9 and the like and method for improving stability of the same |
| US20100055145A1 (en) * | 2008-08-29 | 2010-03-04 | Biosensors International Group | Stent coatings for reducing late stent thrombosis |
| US20100272773A1 (en) | 2009-04-24 | 2010-10-28 | Boston Scientific Scimed, Inc. | Use of Drug Polymorphs to Achieve Controlled Drug Delivery From a Coated Medical Device |
| CN102464669B (zh) * | 2010-11-17 | 2014-04-16 | 浙江海正药业股份有限公司 | 无定形依维莫司及其制备方法 |
| US8669360B2 (en) * | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
| WO2013028208A1 (en) * | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
| CN102786534A (zh) * | 2012-05-25 | 2012-11-21 | 上海现代制药股份有限公司 | 一种依维莫司的制备方法 |
| CA2901162C (en) | 2013-03-15 | 2021-06-01 | Biosensors International Group, Ltd. | Purification of rapamycin derivatives |
-
2014
- 2014-03-17 CA CA2901162A patent/CA2901162C/en active Active
- 2014-03-17 JP JP2016503426A patent/JP2016519086A/ja not_active Withdrawn
- 2014-03-17 SG SG10202112135VA patent/SG10202112135VA/en unknown
- 2014-03-17 WO PCT/US2014/030602 patent/WO2014145780A1/en not_active Ceased
- 2014-03-17 SG SG11201507406YA patent/SG11201507406YA/en unknown
- 2014-03-17 ES ES14763326T patent/ES2897473T3/es active Active
- 2014-03-17 CN CN201480013252.6A patent/CN105102967B/zh active Active
- 2014-03-17 SG SG10201707632PA patent/SG10201707632PA/en unknown
- 2014-03-17 CN CN201811056060.XA patent/CN108864149B/zh active Active
- 2014-03-17 EP EP14763326.7A patent/EP2972258B1/en active Active
-
2015
- 2015-09-14 US US14/853,711 patent/US9598439B2/en active Active
-
2017
- 2017-02-02 US US15/422,593 patent/US10202402B2/en active Active
-
2018
- 2018-12-18 US US16/224,140 patent/US10597406B2/en active Active
-
2019
- 2019-03-07 JP JP2019041615A patent/JP2019089848A/ja active Pending
-
2020
- 2020-03-02 US US16/806,770 patent/US11046711B2/en active Active
-
2021
- 2021-05-06 JP JP2021078418A patent/JP2021121601A/ja active Pending
- 2021-06-28 US US17/360,973 patent/US11780850B2/en active Active
-
2023
- 2023-08-25 JP JP2023136964A patent/JP2023164476A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019089848A5 (enExample) | ||
| RU2010101804A (ru) | Частицы антагониста crth2 | |
| CN103814018A (zh) | 卡巴他赛的晶型 | |
| BRPI0819833B1 (pt) | 5-[(3,3,3-triflúor-2-hidróxi-1-arilpropil)amino]-1h-quinolin-2-onas, seus intermediários, seu uso e seu processos de produção, bem como composição farmacêutica e combinação | |
| CN112079805A (zh) | 一种三氟甲基色酮类化合物的制备方法 | |
| Siddiqui | Sulfamic acid catalysed synthesis of pyranocoumarins in aqueous media | |
| WO2022111564A1 (zh) | 一种吡啶衍生物的消旋方法及应用 | |
| WO2016016852A1 (en) | Process for the purification of canagliflozin | |
| CN105102967B (zh) | 雷帕霉素衍生物的纯化 | |
| Amosova et al. | Cascade regio-and stereoselective reactions of 2-bromomethyl-1, 3-thiaselenole with water and ethylene glycol: En roote to the first representatives of polyfunctional 2, 3-dihydro-1, 4-thiaselenines | |
| CN111253395A (zh) | 萘并[1′,2′:4,5]咪唑并[1,2-a]吡啶-5,6-二酮化合物的合成方法 | |
| JP4933012B2 (ja) | Ｃｏｘ−２抑制剤の製造方法 | |
| Tamura et al. | Syntheses and some properties of 4-acyl-1-methyl-2-azathiabenzene 1-oxides | |
| JP2016534065A (ja) | カバジタキセルの結晶性無水和物形態、その調製方法ならびにその医薬組成物 | |
| CN105693778B (zh) | N-甲氧基甲酰胺导向合成二茂铁并吡啶酮衍生物的方法 | |
| Andrejevic et al. | Poly (arylene ether) s derived from N-alkyl-N-phenyl-3, 5-difluorobenzene sulfonamides: Effect of alkyl chain length on the glass transition temperature | |
| Barton et al. | The synthesis of 1-hydroxy-3-phenylsulphonylpiperidine-2-thione derivatives utilizing methylthiothiocarbonylation as the key original step | |
| CN107721917B (zh) | 一种多取代烟酸酯类化合物的绿色合成方法 | |
| CN107200688B (zh) | 亚甲基富勒烯的异构体选择性合成 | |
| JPS6399024A (ja) | アリ−ルおよびヘテロアリ−ルアルカン酸の製造方法 | |
| JPH0144707B2 (enExample) | ||
| CN115583902B (zh) | 一种炔基硫醚类化合物的制备方法 | |
| CN112159375B (zh) | 一种2，3-二氢呋喃类化合物的绿色制备方法 | |
| JPH0480910B2 (enExample) | ||
| CN102757425B (zh) | 一种硫辛酰肼衍生物其及制备方法和应用 |